Capture_brand and logo.PNG
Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
October 25, 2022 16:05 ET | Morphic Therapeutic
Saturating receptor occupancy at 100 and 200 mg BID doses Statistically significant effects on key lymphocyte subsets WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq:...
Capture_brand and logo.PNG
Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
October 24, 2022 08:00 ET | Morphic Therapeutic
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic-Brand-NoTMLogo-RGB-082321-01.png
Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting
November 15, 2021 09:05 ET | Morphic Therapeutic
αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition Data provide increased rationale to explore integrin inhibition as a component in combination...